Skip to main content

Patel Kinnari's Form 4 filing

Rocket Pharmaceuticals, Inc.RCKT · filed Apr 10, 2025

Accession no.
0001140361-25-013253
Filed
Apr 10, 2025
Trade date
Apr 9, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $99.2K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Patel KinnariCIK 0001725929Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 9, 2025Common StockPPurchaseAcquired+21,099$4.70F1+$99,165.326,774Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On April 9, 2025, the Reporting Person's husband purchased 21,099 shares of Common Stock in a series of brokered transactions at prices ranging from $4.65 to $4.78 and a weighted average price per share of $4.70 (rounded to two decimal places), for an aggregate purchase price of approximately $99,157. The detailed breakdown of executed sales will be furnished upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

President, Head of R&D and Chief Operating Officer

Read the full filing on SEC EDGAR (opens in a new tab)